Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing

Biochemical and Biophysical Research Communications

Volumn 390, Issue 3, 2009, Pages 642-647

  Zhao, Yao ^a   Zhang, Chun lin ^a   Zeng, Bing fang ^a   Wu, Xiao san ^a   Gao, Tian Tian ^a   Oda, Yoshino ^b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Bax; Bcl 2; Chemoresistance; Cyclin D1; Osteosarcoma; RNA interference

Indexed keywords

CYCLIN D1; DOXORUBICIN; LENTIVIRUS VECTOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BCL 2 GENE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STABLE TRANSFECTION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; HUMANS; LENTIVIRUS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE;

LENTIVIRUS;

EID: 70449715116     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.020     Document Type: Article

References (27)

1. Longhi A., Errani C., De Paolis M., Mercuri M., and Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev. 32 (2006) 423-436
2. Lee J.A., Kim M.S., Kim D.H., Lim J.S., Yoo J.Y., Koh J.S., Lee S.Y., Jeon D.G., and Park K.D. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr. Blood Cancer 50 (2008) 195-200
3. Bacci G., Longhi A., Versari M., Mercuri M., Briccoli A., and Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106 (2006) 1154-1161
4. O'Driscoll L. Mechanisms of drug sensitivity and resistance in cancer. Curr. Cancer Drug Targets 9 (2009) 250-251
5. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., Blanchard F., Gouin F., Pitard B., Heymann D., and Redini F. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 67 (2007) 7308-7318
6. Xie X.K., Yang D.S., Ye Z.M., and Tao H.M. Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin. Cancer Invest. 24 (2006) 1-8
7. Khodadadian M., Leroux M.E., Auzenne E., Ghosh S.C., Farquhar D., Evans R., Spohn W., Zou Y., and Klostergaard J. MRP- and BCL-2-mediated drug resistance in human SCLC: effects of apoptotic sphingolipids in vitro. Lung Cancer 66 (2009) 48-57
8. Posl M., Amling M., Werner M., Basler I., Salzer-Kuntschik M., Winkler K., and Delling G. Osteosarcoma-apoptosis and proliferation. Study of bcl-2 expression. Pathology 15 (1994) 337-344
9. Nedelcu T., Kubista B., Koller A., Sulzbacher I., Mosberger I., Arrich F., Trieb K., Kotz R., and Toma C.D. Livin and Bcl-2 expression in high-grade osteosarcoma. J. Cancer Res. Clin. Oncol. 134 (2008) 237-244
10. Eliseev R.A., Dong Y.F., Sampson E., Zuscik M.J., Schwarz E.M., O'Keefe R.J., Rosier R.N., and Drissi M.H. Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene 27 (2008) 3605-3614
11. Katiyar S.K., Roy A.M., and Baliga M.S. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol. Cancer Ther. 4 (2005) 207-216
12. Ye Z., Peng H., Fang Y., Feng J., and Yang D.S. The construction of the eukaryotic expression plasmid pcDNA3.1/azurin and the increased apoptosis of U2OS cells transfected with it. Cell Mol. Biol. Lett. 12 (2007) 407-421
13. Lin H.M., Lee Y.J., Li G., Pestell R.G., and Kim H.R. Bcl-2 induces cyclin D1 promoter activity in human breast epithelial cells independent of cell anchorage. Cell Death Differ. 8 (2001) 44-50
14. Tucker C.A., Kapanen A.I., Chikh G., Hoffman B.G., Kyle A.H., Wilson I.M., Masin D., Gascoyne R.D., Bally M., and Klasa R.J. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Mol. Cancer Ther. 7 (2008) 749-758
15. Oda Y., Matsumoto Y., Harimaya K., Iwamoto Y., and Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol. Rep. 7 (2000) 859-866
16. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16 (1980) 111-120
17. George J., Banik N.L., and Ray S.K. Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem. Res. 34 (2009) 66-78
18. Michaud W.A., Nichols A.C., Mroz E.A., Faquin W.C., Clark J.R., Begum S., Westra W.H., Wada H., Busse P.M., Ellisen L.W., and Rocco J.W. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 15 (2009) 1645-1654
19. Li Y., Tanaka K., Li X., Okada T., Nakamura T., Takasaki M., Yamamoto S., Oda Y., Tsuneyoshi M., and Iwamoto Y. Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells. Int. J. Cancer 121 (2007) 1212-1218
20. Fromigue O., Hay E., Modrowski D., Bouvet S., Jacquel A., Auberger P., and Marie P.J. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 13 (2006) 1845-1856
21. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
22. Tu Y., Xu F.H., Liu J., Vescio R., Berenson J., Fady C., and Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88 (1996) 1805-1812
23. Miller V.M., Xia H., Marrs G.L., Gouvion C.M., Lee G., Davidson B.L., and Paulson H.L. Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. USA 100 (2003) 7195-7200
24. Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., Henderson C.E., and Aebischer P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11 (2005) 423-428
25. Bai J., Nakamura H., Ueda S., Kwon Y.W., Tanaka T., Ban S., and Yodoi J. Proteasome-dependent degradation of cyclin D1 in 1-methyl-4-phenylpyridinium ion (MPP+)-induced cell cycle arrest. J. Biol. Chem. 279 (2004) 38710-38714
26. Takada Y., Khuri F.R., and Aggarwal B.B. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J. Biol. Chem. 279 (2004) 26287-26299
27. Chiu T.L., and Su C.C. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int. J. Mol. Med. 23 (2009) 469-475